Summary
GABA mimetics inhibit extrapyramidal DA and ACh neurons and affeet an unknown system beyond both DA and ACh receptors, which is involved in extrapyramidal motor Outputs. Based on these data, the rationale is discussed for the clinical use of GABA mimetics in Huntington’s chorea, parkinsonian tremor, L-DOPA or neuroleptic-induced dyskinesias.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baraldi,M.,Grandison, L., Guidotti, A.: Distribution and metabolism of muscimol in the brain and other tissues of the rat. Neuropharmacology 18, 57–62 (1979).
Barbeau,A.: L-DOPA therapy in Parkinson’s disease: a critical review of nine years’ experience. Canad. Med. Assoc. J. 101, 59–68 (1969).
Barbeau, A.: Neurological and Psychiatric side-effects of L-DOPA. Pharmacol. Therap. C 1, 475–494 (1976).
Bartholini,G.,Stadler, H., Gadea-Ciria, M., Lloyd, K. G.: The use of the push-pull cannula to estimate the dynamus of acetylcholine and catecholamines within various brain areas. Neuropharmacology 15, 515–519(1976)
Bartholini,G, Scatton,B.,Zivkovic, B. Lloyd, K. G.: On the mode of action of SL 76 002, a new GABA receptor agonist. In: GABA-Neuro- transmitters, pp. 326–339. Copenhagen: Munksgaard. 1979 a.
Bartholini, G., Lloyd, K. G., Worms, P., Constantinidis, J., Tissot, R.: GABA and GABA-ergic medication: relation to striatal dopamine function and parkinsonism. In: Advances in Neurology, Vol. 24, pp. 253–257. New York: Raven Press. 1979 b.
Bernheimer,H, Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seiteiberger, F.: Brain dopamine and the syndroms of Parkinson and Huntington. J. Neurol. Sci. 20, 415–455 (1973).
Calne,D. B.,Klawans, H. L.: Pathophysiology and pharmacotherapy of tremor. Pharmacol. Therap. C 2, 113–123 (1977).
Calne,D. B.,Reid, J. L.: Antiparkinsonian drugs: pharmacological and therapeutic aspects. Drugs 4, 49–72 (1972).
Chase,T. N.,Tamminga, C. A.: GABA system partieipation in human motor, cognitive and neuroendoerine function. In: GABA-Neurotrans- mitters, pp. 283–294. Copenhagen: Munksgaard. 1979.
Desarmenien,M.,Feltz, P., Headley, P. M., Santangelo, F.: Effects of various GABA-mimetics on dorsal ganglion (DRG) neurons: a neuro- physiological analysis. In: GABA and Other Inhibitory Neurotransmitters. Fayetteville: Ankho. 1980 (in press).
Enna,S. J.,Snyder, S. H.: Properties of y-aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions. Brain Res. 100, 81–97 (1975).
Enna,S. J.,Stern, L. Z., Wastek, G. J., Yamamura, H. L.: Minireview: Neurobiology and pharmacology of Huntington’s disease. Life Sci. 20, 205–212 (1977).
Greenblatt,D. L.,Shader, R. I.; Anticholinergics. New Engl. J. Med. 288, 1215–1219 (1973).
Hornykiewicz, O.: Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Revs 18, 925–964 (1966).
Iversen,L. L.,Bird, E. D., Spokes, E., Nicholson, S. H., Suckling, C. J..: Agonist speeifity of GABA binding sites in human brain and GABA in Huntington’s disease and schizophrenia. In: GABA-Neurotransmitters, pp. 179–190. Copenhagen: Munksgaard. 1979.
Kaariainen, I.; Effect of aminooxyacetic acid and baclofen on the catalepsy and on the increase of mesolimbic and striatal dopamine turnover induced by haloperidol in rats. Acta Pharmacol. Toxicol. 39, 393–400 (1976).
Keller,H. H.,Schaffner, R., Haefely, W.: Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn-Schmiedeberg’s Arch. Pharmacol. 294, 1–4 (1976).
Lloyd,K. G.: Indications for GABA neuron dysfunetion in mental disease. In: Enzymes and Neurotransmitters in Mental Disease. New York: RavenPress.1980(inpress).The Potential of GABA Mimetics in the Therapy of Extrapyramidal Disorders 237
Lloyd,K. G.,Davidson, L.: [3H]GABA binding in brains from Huntington’s chorea patients: altered regulation by phospholipids. Science 205, 1147–1149(1979).
Lloyd,K. G.,Dreksler, S.: An analysis of [3H] Gamma-aminobutyric acid (GABA) binding in the human brain. Brain Res. 163, 77–87 (1979).
Lloyd,K. G.,Hornykiewicz, O.: L-glutamic acid decarboxylase in Parkinson’s disease: effect of L-DOPA therapy. Nature243, 521–523 (1973).
Lloyd,K. G.,Worms, P.: Sustained gamma-aminobutyric acid receptor Stimulation and chronic neuroleptic effects. In: Long-Term Effects of Neuroleptics. New York: Raven Press. 1980 (in press).
Lloyd,K. G.,Davidson, L., Hornykiewicz, O.; The neurochemistry of Parkinson’s disease: effect of L-DOPA therapy. J. Pharmacol. Exp. Therap. 195, 453–464 (1975).
Lloyd,K. G.,Shemen, L., Hornykiewicz, O.; Distribution of high affinity sodium-independent (3H)gamma-aminobutyric acid (3H-GABA) binding in the human brain: alterations in Parkinson’s disease. Brain Res. 127, 269–278 (1977 a).
Lloyd,K. G.,Dreksler, S., Bird, E. D.: Alterations in 3H-GABA binding in Huntington’s chorea. Life Sci. 21, 747–754 (1977 b).
Lloyd,K. G.,Worms, P., Depoortere, H., Bartholini, G.: Pharmacological profile of SL 76 002, a new GABA mimetic drug. In: GABA-Neuro- transmitters, pp. 308–325. Copenhagen: Munksgaard. 1979.
Lloyd,K. G.,Worms, P., Zivkovic, B., Scatton, B., Bartholini, G.: Inter- action of GABA mimetics with nigro-striatal dopamine neurons. In: GABA and Other Inhibitory Transmitters. Fayetteville: Ankho. 1980 (in press).
Maggi,A.,Enna, S. J.: Characteristics of muscimol accumulation in mouse brain after systemic administration. Neuropharmacology 18, 361–366 (1979).
Morselli,P. L.,Bossi, L., Henry, J. P., Zarifian, E., Bartholini, G.: On the therapeutic action of SL 76 002, a new GABA mimetic agents: preliminary observations in neuropsychiatric disorders. In: GABA and Other Inhibitory Neurotransmitters. Fayetteville: Ankho. 1980 (in press).
Olsen,R. W.,Wan Ness, P. C., Tourtelotte, W. W.: Gamma-aminobutyric acid receptor binding curves for human brain regions: comparison of Huntington’s disease and normal. In: Huntington’s Disease, pp. 697–704. New York: Raven Press. 1979.
Perry,T. L.,MacLeod, P. M., Hansen, S.: Treatment of Huntington’s chorea with isoniazid. New Engl. J. Med. 297, 840 (1977).
Reisine,T. D.,Beaumont, K.,Bird, E. D., Spokes, E., Yamamura, H. I.; Huntington’s disease: alterations in neurotransmitter receptor binding in the human brain. In: Huntington’s Disease, pp. 717–726. New York: Raven Press. 1979.
Scatton,B.,Bartholini, G.: Modulation of cholinergic transmission in the rat brain by GABA mimetics. In: GABA and Other Inhibitory Transmitters. Fayetteville: Ankho. 1980 (in press).
Schwanz,W.J.,Sharp, F. R., Gunn, R. H., Evarts, E. V.: Lesions of ascending dopaminergic pathways decrease forebrain glucose uptake. Nature261, 155–157 (1976).
Tarsy,D ., Baldessarini, R.J.: The pathophysiologic basis of tardive dyskinesia. Biol. Psychiat. 12, 431–450 (1977).
Worms,P.,Lloyd, K. G.: Biphasic effects of direct, but not indirect, GABA mimetics and antagonists on haloperidol-induced catalepsy. Naunyn- Schmiedeberg’s Arch. Pharmacol. 1980 (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag
About this chapter
Cite this chapter
Bartholini, G., Lloyd, K.G. (1980). The Potential of GABA-Mimetics in the Therapy of Extrapyramidal Disorders. In: Carlsson, A., Jellinger, K., Riederer, P. (eds) Current Topics in Extrapyramidal Disorders. Journal of Neural Transmission, vol 16. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8582-7_26
Download citation
DOI: https://doi.org/10.1007/978-3-7091-8582-7_26
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-8584-1
Online ISBN: 978-3-7091-8582-7
eBook Packages: Springer Book Archive